1. A prospective phase III, randomized, double‐blind, placebo‐controlled study of brodalumab in patients with moderate‐to‐severe plaque psoriasis. (1st August 2016) Authors: Papp, K.A.; Reich, K.; Paul, C.; Blauvelt, A.; Baran, W.; Bolduc, C.; Toth, D.; Langley, R.G.; Cather, J.; Gottlieb, A.B.; Thaçi, D.; Krueger, J.G.; Russell, C.B.; Milmont, C.E.; Li, J.; Klekotka, P.A.; Kricorian, G.; Nirula, A. Journal: British journal of dermatology Issue: Volume 175:Number 2(2016) Page Start: 273 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A prospective phase III, randomized, double‐blind, placebo‐controlled study of brodalumab in patients with moderate‐to‐severe plaque psoriasis4. (23rd June 2016) Authors: Papp, K.A.; Reich, K.; Paul, C.; Blauvelt, A.; Baran, W.; Bolduc, C.; Toth, D.; Langley, R.G.; Cather, J.; Gottlieb, A.B.; Thaçi, D.; Krueger, J.G.; Russell, C.B.; Milmont, C.E.; Li, J.; Klekotka, P.A.; Kricorian, G.; Nirula, A. Journal: British journal of dermatology Issue: Volume 175:Number 2(2016) Page Start: 273 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate‐to‐severe psoriasis. (1st June 2016) Authors: Papp, K.A.; Menter, M.A.; Raman, M.; Disch, D.; Schlichting, D.E.; Gaich, C.; Macias, W.; Zhang, X.; Janes, J.M. Journal: British journal of dermatology Issue: Volume 174:Number 6(2016) Page Start: 1266 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate‐to‐severe psoriasis. (5th April 2016) Authors: Papp, K.A.; Menter, M.A.; Raman, M.; Disch, D.; Schlichting, D.E.; Gaich, C.; Macias, W.; Zhang, X.; Janes, J.M. Journal: British journal of dermatology Issue: Volume 174:Number 6(2016) Page Start: 1266 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. A Randomized, blinded assessor study to Evaluate the efFIcacy and safety of etanercept 50 mg once weekly plus as Needed topical agent vs. Etanercept 50 mg twice weekly in patients with moderate to severe plaque psoriasis (REFINE). (1st July 2014) Authors: Papp, K.A.; Barber, K.; Bissonnette, R.; Bourcier, M.; Lynde, C.W.; Poulin, Y.; Shelton, J.; Toole, J.; Vieira, A.; Poulin‐Costello, M. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 29:Number 2(2015:Feb.) Page Start: 361 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. A Randomized, blinded assessor study to Evaluate the efFIcacy and safety of etanercept 50 mg once weekly plus as Needed topical agent vs. Etanercept 50 mg twice weekly in patients with moderate to severe plaque psoriasis (REFINE). (1st July 2014) Authors: Papp, K.A.; Barber, K.; Bissonnette, R.; Bourcier, M.; Lynde, C.W.; Poulin, Y.; Shelton, J.; Toole, J.; Vieira, A.; Poulin‐Costello, M. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 29:Number 2(2015:Feb.) Page Start: 361 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. A study of the drug secukinumab in the treatment of palmoplantar psoriasis. (1st April 2020) Authors: Gottlieb, A.B.; Kubanov, A.; van Doorn, M.; Sullivan, J.; Papp, K.A.; You, R.; Regnault, P.; Frueh, J.A. Journal: British journal of dermatology Issue: Volume 182:Number 4(2020) Page Start: e139 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. A study of the drug secukinumab in the treatment of palmoplantar psoriasis. (31st March 2020) Authors: Gottlieb, A.B.; Kubanov, A.; van Doorn, M.; Sullivan, J.; Papp, K.A.; You, R.; Regnault, P.; Frueh, J.A. Journal: British journal of dermatology Issue: Volume 182:Number 4(2020) Page Start: e139 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. A study of the drug tildrakizumab for plaque psoriasis. (1st June 2020) Authors: Kimball, A.B.; Papp, K.A.; Reich, K.; Gooderham, M.; Li, Q.; Cichanowitz, N.; La Rosa, C.; Blauvelt, A. Journal: British journal of dermatology Issue: Volume 182:Number 6(2020) Page Start: e196 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. AB0903 Efficacy of tildrakizumab in etanercept partial or nonresponders. (12th June 2018) Authors: Crowley, J.; Papp, K.A.; Hong, C.-H.; Parno, J.; Mendelsohn, A.M.; Li, Q.; Cichanowitz, N.; La Rosa, C. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 1575 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗